Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Prognostic models that identify individuals with chronic kidney disease (CKD) at greatest risk of developing kidney failure help clinicians to make decisions and deliver precision medicine. It is recognised that people with CKD usually have multiple long-term health conditions (multimorbidity) and often experience frailty. We undertook a systematic review to evaluate the representation and consideration of multimorbidity and frailty within CKD cohorts used to develop and/or validate prognostic models assessing the risk of kidney failure.

Methods: We identified studies that described derivation, validation or update of kidney failure prognostic models in MEDLINE, CINAHL Plus and the Cochrane Library-CENTRAL. The primary outcome was representation of multimorbidity or frailty. The secondary outcome was predictive accuracy of identified models in relation to presence of multimorbidity or frailty.

Results: Ninety-seven studies reporting 121 different kidney failure prognostic models were identified. Two studies reported prevalence of multimorbidity and a single study reported prevalence of frailty. The rates of specific comorbidities were reported in a greater proportion of studies: 67.0% reported baseline data on diabetes, 54.6% reported hypertension and 39.2% reported cardiovascular disease. No studies included frailty in model development, and only one study considered multimorbidity as a predictor variable. No studies assessed model performance in populations in relation to multimorbidity. A single study assessed associations between frailty and the risks of kidney failure and death.

Conclusions: There is a paucity of kidney failure risk prediction models that consider the impact of multimorbidity and/or frailty, resulting in a lack of clear evidence-based practice for multimorbid or frail individuals. These knowledge gaps should be explored to help clinicians know whether these models can be used for CKD patients who experience multimorbidity and/or frailty.

Systematic Review Registration: This review has been registered on PROSPERO (CRD42022347295).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470573PMC
http://dx.doi.org/10.1186/s12916-024-03649-9DOI Listing

Publication Analysis

Top Keywords

kidney failure
24
prognostic models
16
multimorbidity frailty
12
failure prognostic
12
multimorbidity
9
representation multimorbidity
8
frailty
8
kidney
8
models
8
prediction models
8

Similar Publications

Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.

Objective: To determine the risk factors for valvular calcification in patients with CKD.

View Article and Find Full Text PDF

Aims: Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF).

Methods And Results: We systematically searched phase 3 randomized clinical trials (RCTs) evaluating diuretic regimens in admitted AHF patients within 48 hours and irrespective of clinical stabilization. We calculated the odds ratio (OR) of FC or FB plus another diuretic (sequential nephron blockade, SNB) compared to FB alone on 24-hour weight loss (WL) and worsening renal function (WRF), with a random-effects model with inverse variance weighting.

View Article and Find Full Text PDF

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.

View Article and Find Full Text PDF

Do psycho-behavioural interventions improve mental and physical health in chronic kidney disease? A systematic review of randomised controlled trials.

J Nephrol

September 2025

Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, Health Psychology Section, King's College London, 5th Floor Bermondsey Wing, Guy's Campus, London Bridge, London, SE1 9RT, UK.

Background: Depression and anxiety are common in chronic kidney disease (CKD) and worsen clinical outcomes. Psycho-behavioural interventions offer a promising, non-pharmacological approach. However, most evidence comes from people with kidney failure with distinct treatment needs, limiting relevance to earlier stages of CKD, where timely support may enhance self-management and slow progression.

View Article and Find Full Text PDF

Renal transplantation is the best option for end-stage renal disease, and in this study, patients who underwent robotic-assisted renal transplantation (RAKT) and open renal transplantation (OKT) were selected to compare their intraoperative and postoperative clinical outcomes: including Operation Time, Length of Stay, WIT (warm ischaemia time), CIT (cold ischaemia time), Estimated Blood Loss, Post 1 month Creatinine, Incision Length, Rewarming Time, Wound infection. The study was registered in PROSPERO with CRD code: CRD420251061084. We searched in Web of Science, Pubmed, Wiely, Elsevier databases, screened according to inclusion and exclusion criteria and finally included 7 papers.

View Article and Find Full Text PDF